Home » Newsletters » BioWorld

BioWorld

June 10, 1994

View Archived Issues

CANGENE'S BOARD TO MEET ON PHARMA PATCH OFFER

CARRINGTON GIVEN OK FOR AIDS TRIAL

MERCK PROVIDES VACCINE TECHNOLOGY TO CHINA

ARRIS FOCUSES ON INHIBITING TRYPTASE

BIOMUNE COMPLETES $5.4M PLACEMENT

NEW COMPANY TO TRANSPLANT HUMAN ISLET CELLS

CAMBRIDGE BIOTECH'S STOCK DELISTED DUE TO AUDIT

LIDAK NETS $8.3M FROM WARRANTS

CLEVELAND CLINIC TURNS RESEARCH INTO ANTISENSE COMPANY

RAC APPROVES GENE THERAPY PROTOCOL FOR ARTHRITIS

FDA PANEL RECOMMENDS APPROVAL OF CENTOCOR'S REOPRO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...